zoledronic acid has been researched along with Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aspord, C; Chaperot, L; Charles, J; Girard, P; Ponsard, B | 1 |
| Chen, L; Curtis, JR; Delzell, E; Saag, KG; Xie, F; Yun, H | 1 |
2 other study(ies) available for zoledronic acid and Infections
| Article | Year |
|---|---|
Potent Bidirectional Cross-Talk Between Plasmacytoid Dendritic Cells and γδT Cells Through BTN3A, Type I/II IFNs and Immune Checkpoints.
Topics: Butyrophilins; Cell Communication; Cell Line, Tumor; Dendritic Cells; Humans; Immunotherapy; Infections; Interferon Type I; Interferon-gamma; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; T-Lymphocytes; Zoledronic Acid | 2020 |
Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab.
Topics: Abatacept; Adalimumab; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Factors; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Immunoconjugates; Infections; Infliximab; Male; Medicare; Middle Aged; Osteoporosis; Proportional Hazards Models; Risk Factors; United States; Zoledronic Acid | 2015 |